Premium
TM6SF2 G lu167 L ys polymorphism is associated with low levels of LDL ‐cholesterol and increased liver injury in obese children
Author(s) -
Grandone A.,
Cozzolino D.,
Marzuillo P.,
Cirillo G.,
Di Sessa A.,
Ruggiero L.,
Di Palma M. R.,
Perrone L.,
Miraglia del Giudice E.
Publication year - 2016
Publication title -
pediatric obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.226
H-Index - 69
eISSN - 2047-6310
pISSN - 2047-6302
DOI - 10.1111/ijpo.12032
Subject(s) - medicine , cholesterol , ldl cholesterol , liver injury , endocrinology
Summary Background The Glu167Lys ( E167K ) transmembrane 6 superfamily member 2 ( TM6SF2 ) variant has been associated with liver steatosis, high alanine transaminase ( ALT ) levels and reduced plasma levels of liver‐derived triglyceride‐rich lipoproteins. Objectives The objectives of this study were to investigate in a group of obese children the association among the 167 K allele of TM6SF2 gene and ALT , cholesterol and triglycerides levels, and hepatic steatosis, and to evaluate the potential interaction between this variant and the I148M patatin like phospholipase 3 gene ( PNPLA3 ) polymorphism on liver enzymes. Methods We genotyped 1010 obese children for TM6SF2 E167K and PNPLA3 I148M polymorphisms. Anthropometrical and biochemical data were collected. Ultrasound imaging of the liver was performed. Results The 167 K allele showed an association with steatosis ( P < 0.0001), higher ALT levels ( P < 0.001) and lower total cholesterol ( P < 0.00001), low‐density lipoprotein cholesterol ( P < 0.0001), triglycerides ( P = 0.02) and non‐high‐density lipoprotein cholesterol levels ( P < 0.1). The subjects homozygous for the PNPLA3 148 M allele carrying the rare variant of TM6SF2 showed an odds ratio of 12.2 (confidence interval 3.8–39.6, P = 0.1) to present hypertransaminasaemia compared with the remaining patients. Conclusion Although the TMS6SF2 E167K variant predisposes the obese children to non‐alcoholic fatty liver disease, there is an association between this variant and lower levels of cardiovascular risk factors. Overall, the data suggest differential effects of TMS6SF2 E167K variant on liver and heart health.